164 related articles for article (PubMed ID: 31715102)
1. Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates.
Ziaei E; Saghaeidehkordi A; Dill C; Maslennikov I; Chen S; Kaur K
Bioconjug Chem; 2019 Dec; 30(12):3098-3106. PubMed ID: 31715102
[TBL] [Abstract][Full Text] [Related]
2. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer.
Saghaeidehkordi A; Chen S; Yang S; Kaur K
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34063098
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and in vitro antitumor activity of a transferrin receptor-targeted peptide-doxorubicin conjugate.
Li S; Zhao H; Fan Y; Zhao G; Wang R; Wen F; Wang J; Wang X; Wang Y; Gao Y
Chem Biol Drug Des; 2020 Jan; 95(1):58-65. PubMed ID: 31452330
[TBL] [Abstract][Full Text] [Related]
8. Intracellular trafficking and cytotoxicity of a gelatine-doxorubicin conjugate in two breast cancer cell lines.
Alvi MM; Nicoletto RE; Eshmawi BA; Kim HK; Cammarata CR; Ofner CM
J Drug Target; 2020 Jun; 28(5):487-499. PubMed ID: 31601131
[TBL] [Abstract][Full Text] [Related]
9. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
10. Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells.
Soudy R; Chen C; Kaur K
J Med Chem; 2013 Oct; 56(19):7564-73. PubMed ID: 24028446
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Cytotoxicity of Peptide Modifications of Doxorubicin on Tetrahymena pyriformis.
Pozdnyakova AN; Cheremnykh EG; Sokolov OY; Kost NV; Shevchenko KV; Shevchenko VP; Nagaev IY; Andreeva LA; Myasoedov NF
Dokl Biochem Biophys; 2021 Mar; 497(1):104-107. PubMed ID: 33895924
[TBL] [Abstract][Full Text] [Related]
12. Conjugation with nanodiamonds via hydrazone bond fundamentally alters intracellular distribution and activity of doxorubicin.
Yuan SJ; Wang C; Xu HZ; Liu Y; Zheng MY; Li K; Sun SK; Komatsu N; Zhao L; Chen X
Int J Pharm; 2021 Sep; 606():120872. PubMed ID: 34246743
[TBL] [Abstract][Full Text] [Related]
13. Trojan-Like Peptide Drug Conjugate Design and Construction for Application in Treatment of Triple-Negative Breast Cancer.
Xiao C; Han J; Bai J; Xia Y; Wang S
J Biomed Nanotechnol; 2021 Aug; 17(8):1554-1563. PubMed ID: 34544533
[TBL] [Abstract][Full Text] [Related]
14. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
15. A Novel Homodimer Peptide-Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy.
Liu S; Tian Y; Jiang S; Wang Z
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902021
[TBL] [Abstract][Full Text] [Related]
16. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
17. Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors.
Furgeson DY; Dreher MR; Chilkoti A
J Control Release; 2006 Jan; 110(2):362-369. PubMed ID: 16303202
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers.
Dong DW; Tong SW; Qi XR
J Biomed Mater Res A; 2013 May; 101(5):1336-44. PubMed ID: 23065848
[TBL] [Abstract][Full Text] [Related]
19. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.
Li S; Zhao H; Mao X; Fan Y; Liang X; Wang R; Xiao L; Wang J; Liu Q; Zhao G
Pharm Res; 2019 Oct; 36(12):168. PubMed ID: 31654226
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment.
Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Balzano-Nogueira L; Huertas-López F; Martí C; Tarazona S; Forteza J; Conesa A; Vicent MJ
Biomaterials; 2018 Dec; 186():8-21. PubMed ID: 30278346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
